Lifeboat Foundation

What’s the optimal way to dose a longevity drug like rapamycin? Nils Osmar looks at some different studies that provide a possible answer:

It’s worth noting that mTORC2 is not directly inhibited by rapamycin under most circumstances, but can be under some. Some studies have found that after prolonged use, rapamycin can also begin inhibiting mTORC2 (see study: Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system).

So taking breaks from rapamycin may also be beneficial.

Continue reading “Rapamycin and Longevity: A Few Thoughts On Dosing” »

Nobel Prize-winning molecular biologist Venki Ramakrishnan sat down with ABC News Live to discuss the science and ethics of extending the human lifespan.

In his new book, “Why We Die: The New Science of Aging and the Quest for Immortality,” Ramakrishnan explains why we may not want to lengthen our lives much longer.

Ramakrishnan’s thought-provoking argument is that a society where people lived for hundreds of years could potentially become stagnant, as it would consist of the same group of people living longer, raising important questions about societal dynamics and progress.

An increase in cancers among people 55 years old and younger may be related to accelerated aging in recent generations, according to a study presented at a conference earlier this month.

Experts say years of research support this, though more questions remain to be answered.

Researchers from the Washington University in St. Louis’s medical school presented the findings from their study on accelerated aging earlier this month at the American Association for Cancer Research Annual Meeting.

Taking mouse lifespan to the next levelmoderatorcaitlin lewisspeakersdanique wortel / aubrey de grey / brian kennedy10:30 AM.

A landmark new study confirms that growing a human being in nine months takes a toll—and multiple pregnancies can have a cumulative effect.

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhDDiscount Links: Epigenetic Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7xyIU-LSYLyQ…

Scientists have tested a novel method of providing cells with healthy mitochondria to fight Parkinson’s disease [1].

Parkinson’s disease is the second-most prevalent neurodegenerative disorder, and it affects 10 million people worldwide. The disease is age-related, as its prevalence rises rapidly in people older than 65, although some people are diagnosed much earlier. Parkinson’s disease is characterized by both motor and mental problems: tremor, rigidity (stiffness), and slowness of movement along with memory and thinking deficits.

Parkinson’s disease is caused by the loss of dopamine-producing (dopaminergic) neurons in a brain region called the substantia nigra. Therapeutic options are limited, and some of the existing ones cause nasty side effects.

We depend on our cells being able to divide and multiply, whether it’s to replace sunburnt skin or replenish our blood supply and recover from injury. Chromosomes, which carry all of our genetic instructions, must be copied in a complete way during cell division. Telomeres, which cap the ends of chromosomes, play a critical role in this cell-renewal process—with a direct bearing on health and disease.

Researchers from Washington University School of Medicine suggest accelerated biological aging may be driving early-onset cancer rates in young people.